Rathbones Group PLC Acquires New Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Rathbones Group PLC bought a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 10,145 shares of the company’s stock, valued at approximately $69,000.

Several other hedge funds have also made changes to their positions in RXRX. The Manufacturers Life Insurance Company lifted its holdings in shares of Recursion Pharmaceuticals by 11.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 124,654 shares of the company’s stock worth $821,000 after buying an additional 13,041 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in shares of Recursion Pharmaceuticals in the 3rd quarter worth $439,000. Stifel Financial Corp lifted its holdings in shares of Recursion Pharmaceuticals by 48.8% in the 3rd quarter. Stifel Financial Corp now owns 161,978 shares of the company’s stock worth $1,067,000 after buying an additional 53,103 shares during the period. State Street Corp lifted its holdings in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after buying an additional 4,120,685 shares during the period. Finally, Wellington Management Group LLP bought a new position in shares of Recursion Pharmaceuticals in the 3rd quarter worth $692,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Up 17.1 %

Shares of NASDAQ:RXRX opened at $4.65 on Thursday. The business’s 50-day moving average is $6.92 and its 200 day moving average is $6.86. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The firm has a market capitalization of $1.87 billion, a P/E ratio of -3.04 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm’s revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.42) EPS. On average, research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on RXRX shares. KeyCorp reduced their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research report on Friday, February 28th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $8.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.